KR20240055976A - Composition for preventing, ameliorating or treating obesity and diabetes mellitus comprising mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as effective component - Google Patents
Composition for preventing, ameliorating or treating obesity and diabetes mellitus comprising mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as effective component Download PDFInfo
- Publication number
- KR20240055976A KR20240055976A KR1020220135973A KR20220135973A KR20240055976A KR 20240055976 A KR20240055976 A KR 20240055976A KR 1020220135973 A KR1020220135973 A KR 1020220135973A KR 20220135973 A KR20220135973 A KR 20220135973A KR 20240055976 A KR20240055976 A KR 20240055976A
- Authority
- KR
- South Korea
- Prior art keywords
- mixture
- lecithin
- castor oil
- cane sugar
- cissus quadrangularis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 122
- 235000000470 Vitis quadrangularis Nutrition 0.000 title claims abstract description 81
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 title claims abstract description 66
- 229930006000 Sucrose Natural products 0.000 title claims abstract description 66
- 229960004793 sucrose Drugs 0.000 title claims abstract description 66
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 title claims abstract description 62
- 239000004359 castor oil Substances 0.000 title claims abstract description 62
- 235000019438 castor oil Nutrition 0.000 title claims abstract description 62
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 title claims abstract description 62
- 239000000787 lecithin Substances 0.000 title claims abstract description 62
- 235000010445 lecithin Nutrition 0.000 title claims abstract description 62
- 229940067606 lecithin Drugs 0.000 title claims abstract description 62
- 229960001777 castor oil Drugs 0.000 title claims abstract description 45
- 208000008589 Obesity Diseases 0.000 title claims abstract description 44
- 235000020824 obesity Nutrition 0.000 title claims abstract description 44
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 27
- 244000045483 Cissus quadrangularis Species 0.000 title claims abstract 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 230000036541 health Effects 0.000 claims abstract description 24
- 235000013376 functional food Nutrition 0.000 claims abstract description 17
- 230000003579 anti-obesity Effects 0.000 claims abstract description 8
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000003674 animal food additive Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract description 29
- 230000003078 antioxidant effect Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 244000262406 Vitis quadrangularis Species 0.000 description 70
- 238000002835 absorbance Methods 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 6
- 102000019280 Pancreatic lipases Human genes 0.000 description 6
- 108050006759 Pancreatic lipases Proteins 0.000 description 6
- 108010028144 alpha-Glucosidases Proteins 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229940116369 pancreatic lipase Drugs 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 5
- -1 For example Chemical class 0.000 description 5
- 229960002632 acarbose Drugs 0.000 description 5
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940040461 lipase Drugs 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QKPLRMLTKYXDST-NSEZLWDYSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride Chemical compound Cl.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O QKPLRMLTKYXDST-NSEZLWDYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000017003 Cissus Nutrition 0.000 description 1
- 241001355260 Cissus Species 0.000 description 1
- 235000017014 Cissus repens Nutrition 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 235000004000 Cyclopia intermedia Nutrition 0.000 description 1
- 244000110556 Cyclopia subternata Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000020340 honeybush tea Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000009329 organic farming Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/184—Emulsifier
- A23V2250/1842—Lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/48—Ultrasonic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방, 개선 또는 치료용 조성물에 관한 것으로, 상세하게는 본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물은 항산화 활성을 나타내고, 시서스 쿼드란굴라리스 추출물 단독에 비해 항비만 및 항당뇨 효과가 더 우수하므로, 비만 및 당뇨병 관련 건강기능식품, 의약품 등에 매우 유용하게 활용될 수 있다.The present invention relates to a composition for preventing, improving or treating obesity and diabetes, comprising a mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as active ingredients, and specifically, the composition of the present invention. A mixture of refined cane sugar, lecithin, castor oil and Cissus quadrangularis exhibits antioxidant activity and has better anti-obesity and anti-diabetic effects compared to Cissus quadrangularis extract alone, thereby improving obesity and diabetes-related health. It can be very useful in functional foods, medicines, etc.
Description
본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, improving or treating obesity and diabetes, comprising a mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as active ingredients.
비만은 '건강을 해칠 정도로 체내 지방이 과도하게 축적된 상태'로 정의하며, 외형적 문제뿐만 아니라, 비만이 당뇨병이나 동맥경화증 등 각종 질병의 원인으로 밝혀지면서 반드시 치료되어야 하는 '만성질환'이라는 인식이 확립되고 있다.Obesity is defined as ‘a condition in which body fat accumulates excessively to the point of harming health.’ In addition to external problems, obesity has been recognized as a ‘chronic disease’ that must be treated as it has been found to be the cause of various diseases such as diabetes and arteriosclerosis. This is being established.
세계보건기구(WHO)에 따르면, 현재 전 세계적으로 과체중 혹은 비만에 해당되는 사람들의 숫자는 12억 명에 이르며, 년간 약 30만 명이 비만과 관련된 질환으로 사망한다고 보고되고 있다.According to the World Health Organization (WHO), the number of people worldwide who are currently overweight or obese is 1.2 billion, and it is reported that about 300,000 people die every year from diseases related to obesity.
비만이 여러 가지 질병에 미치는 영향은 매우 심각하여 전 세계 당뇨병 환자의 80%, 심장질환의 21%가 비만이 원인인 것으로 알려져 있다. 이외에도 자궁암, 신장암, 유방암 등 각종 암도 비만과 직간접적으로 연관되어 있으며 비만이나 과체중의 경우 수면무호흡증, 골관절염, 담석증 등의 발병률도 정상인보다 높다고 한다. 이처럼 비만이 건강에 미치는 영향은 매우 심각하다고 할 수 있다.The impact of obesity on various diseases is very serious, and it is known that 80% of diabetes patients and 21% of heart diseases worldwide are caused by obesity. In addition, various cancers such as uterine cancer, kidney cancer, and breast cancer are directly or indirectly related to obesity, and in the case of obesity or overweight, the incidence of sleep apnea, osteoarthritis, and gallstones is said to be higher than that of normal people. As such, the impact of obesity on health can be said to be very serious.
사회, 경제적인 측면에서도 비만으로 인한 손실은 매우 크다. 미국의 경우, 미국인의 평균체중은 지난 90년대에 약 10파운드(4.5㎏)가 늘어났으며, 비만으로 인해 매년 약 1170억 달러의 직간접 경비가 지출되고 있다. 우리나라의 경우에도 2001년 '국민건강 영향 조사'에 따르면 비만으로 인한 사회, 경제적 비용이 1조 17억 원에 달한다고 한다. 이러한 액수는 비만 관련 질병으로 인한 총진료비와 조기사망, 입원 등으로 인한 생산성 손실을 합산한 것으로 국민 의료비의 약 5%에 해당하는 높은 수치이다. 또한, 비만인구는 현재 전세계적으로 2억5,000만 명에 달하고, 오는 2025년에 이르면 3억 명 이상 될 것으로 예측되고 있다. 세계보건기구(WHO)는 '위험에 대한 예방, 건강한 생활에 대한 추구'라는 보고서를 통해 비만을 각종 질병, 장애 및 사망의 핵심적인 원인으로 지적하고 있다. 국내 비만인구도 갈수록 급증하고 있는 추세다. 국민건강영양조사에 따르면, 한국의 비만인구(BMI: 25~30)는 1995년 남녀 각각 전체 인구의 11.7%, 18.0%이었으나, 2001년에는 전체 인구의 26.5%(남자), 25.9%(여자)로 급증, 계속적인 증가 추세를 보이고 있다.From a social and economic perspective, the losses due to obesity are very large. In the United States, the average weight of Americans has increased by about 10 pounds (4.5 kg) in the 1990s, and obesity costs about $117 billion in direct and indirect costs every year. In Korea, according to the 2001 National Health Impact Survey, the social and economic costs of obesity amount to 1.017 trillion won. This amount is a combination of total medical expenses due to obesity-related diseases and productivity loss due to premature death and hospitalization, and is a high figure equivalent to about 5% of national medical expenses. In addition, the number of obese people worldwide currently reaches 250 million, and it is predicted that the number will increase to more than 300 million by 2025. The World Health Organization (WHO) points out obesity as a key cause of various diseases, disabilities, and death through a report titled ‘Prevention of Risk, Pursuit of Healthy Life’. The obese population in Korea is also rapidly increasing. According to the National Health and Nutrition Examination Survey, Korea's obese population (BMI: 25-30) was 11.7% and 18.0% of the total population for men and women, respectively, in 1995, but in 2001, it was 26.5% (men) and 25.9% (women) of the total population. has rapidly increased and continues to increase.
비만은 한 가지 원인으로 발생하는 질병이 아니라 유전적, 환경-사회적, 정신적인 여러 가지 요인들이 복합적으로 작용하여 발생하기 때문에 어느 한 가지 방법으로 치료하기는 어렵다. 즉, 비만은 에너지 소모량에 비해 에너지 섭취량이 많을 경우에 발생하기 때문에 비만치료는 결국 섭취하는 에너지보다 소비하는 에너지를 많게 하여 에너지 불균형을 교정하는 것이다. 현재 비만을 치료하기 위한 방법은 식사요법, 운동요법, 행동요법 등 생활 습관을 교정하는 방법과 약물치료 및 수술적 치료로 나눌 수 있다. 이 중에서 약물이나 수술적 치료에 앞서 생활습관을 교정하기 위한 적극적인 노력이 선행되어야 하지만 생활습관을 교정하는 일이 쉽지 않을 뿐 아니라 생활습관 교정만으로 감소시킬 수 있는 체중은 한계가 있다. 따라서 많은 경우에 생활습관 교정과 함께 약물치료가 필요하다.Obesity is not a disease caused by a single cause, but is caused by a complex combination of genetic, environmental-social, and psychological factors, so it is difficult to treat with just one method. In other words, obesity occurs when energy intake is greater than energy consumption, so obesity treatment ultimately corrects energy imbalance by increasing energy consumption rather than energy intake. Current methods to treat obesity can be divided into lifestyle correction methods such as diet therapy, exercise therapy, and behavioral therapy, as well as drug treatment and surgical treatment. Among these, active efforts to correct lifestyle habits must be made prior to drug or surgical treatment, but not only is it not easy to correct lifestyle habits, but there is a limit to the weight that can be lost through lifestyle modification alone. Therefore, in many cases, drug treatment along with lifestyle modification is necessary.
현재 미국 FDA가 장기사용을 승인한 비만치료 약물은 2가지 뿐으로 노르에피네프린(norepinephrine)과 세로토닌(serotonin)의 재흡수를 억제하는 작용을 가진 시부트라민(sibutramine; Reductil)과 췌장 및 소화기계에서 분비되는 리파제(lipase)를 억제하는 효과를 나타내는 오르리스타트(orlistat; Xenical)가 있다.Currently, there are only two obesity treatment drugs approved by the U.S. FDA for long-term use: sibutramine (Reductil), which has the effect of inhibiting the reuptake of norepinephrine and serotonin, and lipase secreted by the pancreas and digestive system. There is orlistat (Xenical), which has the effect of inhibiting lipase.
그러나 이 두 가지 약물 모두 몇 가지 제한점으로 인해 널리 사용되지는 못하고 있다. 시부트라민(Sibutramine)의 경우, 혈압상승, 불면증, 구강건조, 어지러움 등의 부작용이 비교적 흔하고, 심혈관질환 또는 조절되지 않는 고혈압을 가진 환자에게는 사용할 수 없는 단점이 있다. 오르리스타트(Orlistat)의 경우에는 설사, 지방변, 분실금 등의 부작용이 흔하고 한국인과 같이 지방섭취가 서양인에 비해 적은 경우에는 약물의 효과가 뚜렷하지 않다는 점으로 인해 사용이 제한되고 있다. 또한 두 가지 약물 모두 아직까지는 장기간 사용시의 안전성에 대한 연구가 더 필요한 상황이다.However, both of these drugs are not widely used due to several limitations. In the case of Sibutramine, side effects such as increased blood pressure, insomnia, dry mouth, and dizziness are relatively common, and it has the disadvantage that it cannot be used in patients with cardiovascular disease or uncontrolled high blood pressure. In the case of Orlistat, side effects such as diarrhea, steatorrhea, and incontinence are common, and its use is limited in Koreans who consume less fat than Westerners due to the lack of clear drug effects. In addition, both drugs still require further research on their safety during long-term use.
항비만 관련 선행기술로는 한국등록특허 제2292060호에 '인슐리나 및 허니부쉬의 조합추출물을 유효성분으로 포함하는 비만증의 치료 또는 예방용 조성물'이 개시되어 있으며, 한국등록특허 제1923603호에 '녹차 복합 추출물을 유효성분으로 포함하는 항비만 조성물'이 개시되어 있다. 하지만, 본 발명의 '비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방, 개선 또는 치료용 조성물'에 대해서는 아직까지 개시된 바가 없다.As anti-obesity related prior art, Korean Patent No. 2292060 discloses ‘Composition for the treatment or prevention of obesity containing a combination extract of insulin and honeybush as an active ingredient’, and Korean Patent No. 1923603 discloses ‘Composition for the treatment or prevention of obesity. An anti-obesity composition comprising green tea complex extract as an active ingredient is disclosed. However, the present invention's 'composition for preventing, improving or treating obesity and diabetes comprising a mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as active ingredients' has not yet been disclosed. .
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방, 개선 또는 치료용 조성물을 제공하고, 본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물이 항산화 활성을 나타내며, 시서스 쿼드란굴라리스 추출물 단독에 비해 항비만 및 항당뇨 효과가 더 우수한 것을 확인함으로써, 본 발명을 완성하였다.The present invention was derived from the above needs, and the present invention provides a method for preventing, improving or treating obesity and diabetes, comprising a mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as active ingredients. Provided is a composition for use, wherein the mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis exhibits antioxidant activity and has anti-obesity and anti-diabetic effects compared to Cissus quadrangularis extract alone. The present invention was completed by confirming that it is superior.
상기 과제를 해결하기 위하여, 본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스(Cissus quadrangularis)의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In order to solve the above problems, the present invention provides a health functional food for preventing or improving obesity and diabetes containing a mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as active ingredients. A composition is provided.
또한, 본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스(Cissus quadrangularis)의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방 또는 치료용 약학 조성물을 제공한다.Additionally, the present invention provides a pharmaceutical composition for preventing or treating obesity and diabetes, comprising a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis as active ingredients.
또한, 본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스(Cissus quadrangularis)의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방 또는 개선용 사료첨가제를 제공한다.In addition, the present invention provides a feed additive for preventing or improving obesity and diabetes, comprising a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis as active ingredients.
또한, 본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스(Cissus quadrangularis)의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방 또는 치료용 수의학적 조성물을 제공한다.In addition, the present invention provides a veterinary composition for preventing or treating obesity and diabetes, comprising a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis as active ingredients.
또한, 본 발명은 1) 비정제 사탕수수당 및 레시틴에 물을 첨가하여 혼합하는 단계; 2) 상기 단계 1)의 혼합물에 피마자유를 첨가하여 혼합하는 단계; 및 3) 상기 단계 2)의 최종 혼합물에 시서스 쿼드란굴라리스(Cissus quadrangularis) 분말 및 물을 첨가하여 혼합한 후, 초음파 처리하는 단계;를 포함하여 제조되는 것을 특징으로 하는 항비만 및 항당뇨 효과를 갖는 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물의 제조 방법을 제공한다.In addition, the present invention includes the steps of 1) adding water to unrefined cane sugar and lecithin and mixing them; 2) adding castor oil to the mixture of step 1) and mixing; and 3) adding and mixing Cissus quadrangularis powder and water to the final mixture of step 2), followed by ultrasonic treatment. A method for preparing an effective mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis is provided.
본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물을 포함하는 비만 및 당뇨병의 예방, 개선 또는 치료용 조성물에 관한 것으로, 상세하게는 본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물은 항산화 활성을 나타내고, 시서스 쿼드란굴라리스 단독 추출물에 비해 항비만 및 항당뇨 효과가 더 우수하다.The present invention relates to a composition for preventing, improving or treating obesity and diabetes comprising a mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis, and in particular, the unrefined cane sugar of the present invention. A mixture of sugar, lecithin, castor oil and Cissus quadrangularis exhibits antioxidant activity and has better anti-obesity and anti-diabetic effects compared to Cissus quadrangularis extract alone.
도 1은 본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물의 항산화 활성을 확인한 결과이다. BHT(butylated hydroxytoluene)는 양성대조군이고, 추출물은 시서스 쿼드란굴라리스 추출물 단독 처리군이며, 혼합물은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물 처리군이다.
도 2는 본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물의 췌장 리파아제 저해 활성을 확인한 결과이다. EGCG(Epigallro Catechine Gallate)는 양성대조군이고, 추출물은 시서스 쿼드란굴라리스 추출물 단독 처리군이며, 혼합물은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물 처리군이다.
도 3은 본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물의 3T3-L1 지방전구세포에 대한 세포 독성을 확인한 결과이다. n은 아무것도 처리하지 않은 군이고, 추출물은 시서스 쿼드란굴라리스 추출물 단독 처리군이며, 혼합물은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물 처리군이다.
도 4는 본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물의 지방축적 억제 활성을 확인한 결과이다. N은 아무것도 처리하지 않은 군이고, C는 분화유도 물질(MDI)을 처리하여 분화를 유도한 군이며, 추출물은 시서스 쿼드란굴라리스 추출물 단독 처리군이며, 혼합물은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물 처리군이다.
도 5는 본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물의 α-글루코시다아제 저해 활성을 확인한 결과이다. ACA(acarbose)는 양성대조군이고, 추출물은 시서스 쿼드란굴라리스 추출물 단독 처리군이며, 혼합물은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물 처리군이다.Figure 1 shows the results of confirming the antioxidant activity of a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis of the present invention. BHT (butylated hydroxytoluene) is a positive control group, the extract is a group treated with Cissus quadrangularis extract alone, and the mixture is a group treated with a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis.
Figure 2 shows the results of confirming the pancreatic lipase inhibitory activity of a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis of the present invention. EGCG (Epigallro Catechine Gallate) is a positive control group, the extract is a group treated with Cissus quadrangularis extract alone, and the mixture is a group treated with a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis.
Figure 3 shows the results of confirming the cytotoxicity of the mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis of the present invention on 3T3-L1 preadipocytes. n is a group that was not treated with anything, the extract is a group treated with Cissus quadrangularis extract alone, and the mixture is a group treated with a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis.
Figure 4 shows the results of confirming the fat accumulation inhibition activity of the mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis of the present invention. N is a group that was not treated with anything, C is a group that induced differentiation by treatment with a differentiation inducing agent (MDI), the extract is a group treated with Cissus quadrangularis extract alone, and the mixture is unrefined cane sugar and lecithin. , a mixture treatment group of castor oil and Cissus quadrangularis.
Figure 5 shows the results of confirming the α-glucosidase inhibitory activity of a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis of the present invention. ACA (acarbose) is a positive control group, the extract is a group treated with Cissus quadrangularis extract alone, and the mixture is a group treated with a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis.
본 발명의 목적을 달성하기 위하여, 본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스(Cissus quadrangularis)의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In order to achieve the purpose of the present invention, the present invention provides a health product for preventing or improving obesity and diabetes, comprising a mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as active ingredients. Provided is a nutraceutical composition.
본 발명의 비만 및 당뇨병의 예방 또는 개선용 건강기능식품 조성물에서, 상기 혼합물은In the health functional food composition for preventing or improving obesity and diabetes of the present invention, the mixture
1) 비정제 사탕수수당 및 레시틴에 물을 첨가하여 혼합하는 단계;1) Adding and mixing unrefined cane sugar and lecithin with water;
2) 상기 단계 1)의 혼합물에 피마자유를 첨가하여 혼합하는 단계; 및2) adding castor oil to the mixture of step 1) and mixing; and
3) 상기 단계 2)의 최종 혼합물에 시서스 쿼드란굴라리스(Cissus quadrangularis) 분말 및 물을 첨가하여 혼합한 후, 초음파 처리하는 단계;를 포함하여 제조될 수 있으나, 이에 제한되지 않는다.3) adding and mixing Cissus quadrangularis powder and water to the final mixture of step 2), followed by ultrasonic treatment; but is not limited thereto.
상기 혼합물은 조성물 전체 중량에 대하여 0.5~5.0 중량%의 비정제 사탕수수당, 0.5~5.0 중량%의 레시틴, 0.01~2.0 중량%의 피마자유 및 0.1~4.0 중량%의 시서스 쿼드란굴라리스 분말을 포함할 수 있으며, 바람직하게는 상기 혼합물은 조성물 전체 중량에 대하여 1.5~3.5 중량%의 비정제 사탕수수당, 1.5~3.5 중량%의 레시틴, 0.05~1.0 중량%의 피마자유 및 0.5~2.0 중량%의 시서스 쿼드란굴라리스 분말을 포함할 수 있으며, 더 바람직하게는 상기 혼합물은 조성물 전체 중량에 대하여 2.5 중량%의 비정제 사탕수수당, 2.5 중량%의 레시틴, 0.1 중량%의 피마자유 및 1.0 중량%의 시서스 쿼드란굴라리스 분말을 포함할 수 있으나, 이에 제한되지 않는다.The mixture contains 0.5 to 5.0% by weight of unrefined cane sugar, 0.5 to 5.0% by weight of lecithin, 0.01 to 2.0% by weight of castor oil, and 0.1 to 4.0% by weight of Cissus quadrangularis powder, based on the total weight of the composition. It may include, preferably, the mixture is 1.5 to 3.5% by weight of unrefined cane sugar, 1.5 to 3.5% by weight of lecithin, 0.05 to 1.0% by weight of castor oil, and 0.5 to 2.0% by weight, based on the total weight of the composition. % of Cissus quadrangularis powder, more preferably, the mixture contains 2.5% by weight of unrefined cane sugar, 2.5% by weight of lecithin, 0.1% by weight of castor oil and It may include, but is not limited to, 1.0% by weight of Cissus quadrangularis powder.
상기 비정제 사탕수수당은 사탕수수에서 수득한 원당을 여러 차례에 걸쳐 정제하여 제조하는 백, 황, 흑설탕과는 달리, 유기농법으로 재배된 사탕수수에서 수득한 원당을 정제하지 않은 설탕이다.Unlike white, yellow, and brown sugar, which are manufactured by refining raw sugar obtained from sugar cane several times, the unrefined cane sugar is sugar obtained from sugar cane grown through organic farming and has not been refined.
상기 당뇨병은 제2형 당뇨병일 수 있으나, 이에 제한되지 않는다.The diabetes may be type 2 diabetes, but is not limited thereto.
상기 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조될 수 있지만, 이에 한정하는 것은 아니다. The composition may be manufactured in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage, but is not limited thereto.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 양은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 총 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취인 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When using the health functional food composition of the present invention as a food additive, the health functional food composition may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of active ingredient can be appropriately used depending on the purpose of use (prevention or improvement). Generally, when manufacturing a food or beverage, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the total raw materials. However, in the case of long-term intake for health purposes, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There are no particular restrictions on the types of health functional foods. Examples of foods to which the health functional food composition can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, and tea. There are drinks, alcoholic beverages, and vitamin complexes, and it includes all health foods in the conventional sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함할 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.Additionally, the health functional food composition of the present invention can be manufactured into food, especially functional food. The functional food of the present invention includes ingredients commonly added during food production, and includes, for example, proteins, carbohydrates, fats, nutrients and seasonings. For example, when manufactured as a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, etc.), or sugar alcohols (e.g., For example, xylitol, sorbitol, erythritol, etc.) is preferable. The flavoring agent may be a natural flavoring agent (e.g., thaumatin, stevia extract, etc.) or a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above health functional food composition, various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonic acid. It may further contain carbonating agents used in beverages. The ratio of the ingredients added is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
또한, 본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스(Cissus quadrangularis)의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방 또는 치료용 약학 조성물을 제공한다.Additionally, the present invention provides a pharmaceutical composition for preventing or treating obesity and diabetes, comprising a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis as active ingredients.
본 발명에 따른 상기 약학 조성물은 각각 통상의 방법에 따라 캡슐제, 산제, 과립제, 정제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. The pharmaceutical composition according to the present invention can be formulated and used in the form of oral dosage forms such as capsules, powders, granules, tablets, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods. You can.
본 발명에 따른 상기 약학 조성물은 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더 포함할 수 있다. The pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent.
본 발명의 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한 다양한 화합물 혹은 혼합물을 들 수 있다. Carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate. , cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 약학 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당하는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로골, 트윈 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. in the pharmaceutical composition. It is prepared by mixing. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, syrups, etc. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, wethepsol, macrogol, Tween 61, cacao, laurin, glycerogelatin, etc. can be used.
본 발명의 약학 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다.The appropriate dosage of the pharmaceutical composition of the present invention may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity. You can.
본 발명의 약학 조성물은 경구 또는 비경구로 투여할 수 있으며, 비경구투여의 경우, 피부에 국소적으로 도포, 정맥 내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있다.The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered topically on the skin, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc.
또한, 본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스(Cissus quadrangularis)의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방 또는 개선용 사료첨가제를 제공한다.In addition, the present invention provides a feed additive for preventing or improving obesity and diabetes, comprising a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis as active ingredients.
본 발명의 사료 첨가제는 사료관리법상의 보조사료에 해당한다. 본 발명에서 용어 '사료'는 동물이 먹고, 섭취하며, 소화시키기 위한 또는 이에 적당한 임의의 천연 또는 인공 규정식, 한끼식 등 또는 상기 한끼식의 성분을 의미할 수 있다. 상기 사료의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용되는 사료를 사용할 수 있다. 상기 사료의 비제한적인 예로는, 곡물류, 근과류, 식품 가공 부산물류, 조류, 섬유질류, 제약 부산물류, 유지류, 전분류, 박류 또는 곡물 부산물류 등과 같은 식물성 사료; 단백질류, 무기물류, 유지류, 광물성류, 유지류, 단세포 단백질류, 동물성 플랑크톤류 또는 음식물 등과 같은 동물성 사료를 들 수 있다. 이들은 단독으로 사용되거나 2종 이상을 혼합하여 사용될 수 있다.The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act. In the present invention, the term 'feed' may mean any natural or artificial diet, meal, etc., or a component of the meal, for or suitable for eating, ingestion, and digestion by animals. The type of feed is not particularly limited, and feed commonly used in the art can be used. Non-limiting examples of the feed include plant feeds such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, cucurbits or grain by-products; Examples include animal feeds such as proteins, inorganic substances, fats and oils, minerals, fats and oils, single-cell proteins, zooplanktons or food. These may be used alone or in combination of two or more types.
또한, 본 발명은 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스(Cissus quadrangularis)의 혼합물을 유효성분으로 포함하는 비만 및 당뇨병의 예방 또는 치료용 수의학적 조성물을 제공한다.In addition, the present invention provides a veterinary composition for preventing or treating obesity and diabetes, comprising a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis as active ingredients.
본 발명의 수의학적 조성물은 통상의 방법에 따른 적절한 부형제 및 희석제를 더 포함할 수 있다. 본 발명의 수의학적 조성물에 포함될 수 있는 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시 벤조에이트, 탈크, 마그네슘 스테아레이트, 세탄올, 스테아릴알콜, 유동파라핀, 솔비탄모노스테아레이트, 폴리소르베이트 60, 메칠파라벤, 프로필파라벤 및 광물유를 들 수 있다. 본 발명에 따른 수의학적 조성물은 충진제, 항응집제, 윤활제, 습윤제, 향신료, 유화제, 방부제 등을 추가로 포함할 수 있는데, 본 발명에 따른 수의학적 조성물은 동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 잘 알려진 방법을 사용하여 제형화될 수 있고, 제형은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 용액, 시럽, 에어로졸, 연질 또는 경질 젤라틴 캅셀, 좌제, 멸균 주사용액, 멸균 외용제 등의 형태일 수 있다. The veterinary composition of the present invention may further include appropriate excipients and diluents according to conventional methods. Excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate. , polysorbate 60, methylparaben, propylparaben, and mineral oil. The veterinary composition according to the present invention may further include fillers, anti-aggregants, lubricants, wetting agents, spices, emulsifiers, preservatives, etc. The veterinary composition according to the present invention provides rapid and sustained release of the active ingredient after administration to an animal. or may be formulated using methods well known in the art to provide sustained release, the dosage form being powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, It may be in the form of a suppository, sterile injectable solution, or sterile topical medication.
본 발명에 따른 수의학적 조성물의 유효한 양은 동물의 개체에 따라 적절하게 선택할 수 있다. 질환 내지 상태의 중증도, 개체의 연령, 체중, 건강상태 또는 성별에 따른 본 발명의 유효성분에 대한 민감도, 투여 경로, 투여 기간, 상기 조성물과 배합 또는 동시 사용되는 다른 조성물을 포함한 요소 및 기타 생리 내지 수의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.The effective amount of the veterinary composition according to the present invention can be appropriately selected depending on the individual animal. Severity of the disease or condition, sensitivity to the active ingredient of the present invention depending on the individual's age, weight, health condition or gender, administration route, administration period, factors including other compositions mixed or used simultaneously with the composition, and other physiological or It can be determined based on factors well known in the veterinary field.
또한, 본 발명은 In addition, the present invention
1) 비정제 사탕수수당 및 레시틴에 물을 첨가하여 혼합하는 단계; 1) Adding and mixing unrefined cane sugar and lecithin with water;
2) 상기 단계 1)의 혼합물에 피마자유를 첨가하여 혼합하는 단계; 및 2) adding castor oil to the mixture of step 1) and mixing; and
3) 상기 단계 2)의 최종 혼합물에 시서스 쿼드란굴라리스(Cissus quadrangularis) 분말 및 물을 첨가하여 혼합한 후, 초음파 처리하는 단계;를 포함하여 제조되는 것을 특징으로 하는 항비만 및 항당뇨 효과를 갖는 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물의 제조 방법을 제공한다.3) Cissus quadrangularis powder and water are added to the final mixture of step 2), mixed, and then sonicated. Anti-obesity and anti-diabetic effects, characterized in that the preparation includes Provided is a method for producing a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis.
본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물의 제조 방법에서, 상기 혼합물은 조성물 전체 중량에 대하여 0.5~5.0 중량%의 비정제 사탕수수당, 0.5~5.0 중량%의 레시틴, 0.01~2.0 중량%의 피마자유 및 0.1~4.0 중량%의 시서스 쿼드란굴라리스 분말을 포함할 수 있으며, 바람직하게는 상기 혼합물은 조성물 전체 중량에 대하여 1.5~3.5 중량%의 비정제 사탕수수당, 1.5~3.5 중량%의 레시틴, 0.05~1.0 중량%의 피마자유 및 0.5~2.0 중량%의 시서스 쿼드란굴라리스 분말을 포함할 수 있으며, 더 바람직하게는 상기 혼합물은 조성물 전체 중량에 대하여 2.5 중량%의 비정제 사탕수수당, 2.5 중량%의 레시틴, 0.1 중량%의 피마자유 및 1.0 중량%의 시서스 쿼드란굴라리스 분말을 포함할 수 있으나, 이에 제한되지 않는다.In the method for producing a mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis of the present invention, the mixture contains 0.5 to 5.0% by weight of unrefined cane sugar, 0.5 to 5.0% by weight based on the total weight of the composition. It may include % by weight of lecithin, 0.01-2.0% by weight of castor oil, and 0.1-4.0% by weight of Cissus quadrangularis powder, and preferably the mixture contains 1.5-3.5% by weight based on the total weight of the composition. It may include unrefined cane sugar, 1.5-3.5% by weight of lecithin, 0.05-1.0% by weight of castor oil, and 0.5-2.0% by weight of Cissus quadrangularis powder, and more preferably, the mixture is a composition It may include, but is not limited to, 2.5% by weight of unrefined cane sugar, 2.5% by weight of lecithin, 0.1% by weight of castor oil, and 1.0% by weight of Cissus quadrangularis powder.
이하, 본 발명의 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail through examples. However, the following examples only illustrate the present invention, and the content of the present invention is not limited to the following examples.
제조예 1. 혼합물 제조Preparation Example 1. Preparation of mixture
조성물 전체 중량 기준으로, 2.5 중량%의 비정제 사탕수수당(AUNO MINERAL RAW SUGAR, AUNO Co.) 및 2.5 중량%의 레시틴(레시틴 분말, (주)ES 식품원료)에 62.6 중량%의 물을 첨가하여 30~40℃에서 2분간 호모믹서를 이용하여 고속 교반한 후, 0.1 중량%의 피마자유(castor oil, USA, Now Foods Co.)를 첨가하여 상온에서 호모믹서를 이용하여 저속 교반하였다. 이후에, 1 중량%의 시서스 쿼드란굴라리스(Cissus quadrangularis) 분말(CISSUS POWDER EXTRACT 20X, Canada, Renu Bio Health Ltd.) 및 31.3 중량%의 물을 첨가하여 상온에서 2.5분간 고속 교반하고, 2.5분간 저속 교반한 다음 3분간 초음파 처리(30KHZ, Handheld Portable Ultrasonic Homogenizer, Mdoel : BKSH-150)하여 혼합물을 제조하였다(표 1). 시서스 쿼드란굴라리스 단독 추출물은 1 중량%의 시서스 쿼드란굴라리스 분말에 99.9 중량%의 물을 첨가하여 상온에서 2.5분간 고속 교반하고, 2.5분간 저속 교반한 다음 3분간 초음파 처리하여 제조하였다. Based on the total weight of the composition, 62.6% by weight of water is added to 2.5% by weight of unrefined cane sugar (AUNO MINERAL RAW SUGAR, AUNO Co.) and 2.5% by weight of lecithin (lecithin powder, ES Food Ingredients Co., Ltd.) After stirring at high speed using a homomixer at 30-40°C for 2 minutes, 0.1% by weight of castor oil (Castor oil, USA, Now Foods Co.) was added and stirred at low speed using a homomixer at room temperature. Afterwards, 1% by weight of Cissus quadrangularis powder (CISSUS POWDER EXTRACT 20X, Canada, Renu Bio Health Ltd.) and 31.3% by weight of water were added, stirred at high speed for 2.5 minutes at room temperature, and stirred at high speed for 2.5 minutes. The mixture was prepared by stirring at low speed for a minute and then ultrasonication (30KHZ, Handheld Portable Ultrasonic Homogenizer, Mdoel: BKSH-150) for 3 minutes (Table 1). Cissus quadrangularis sole extract was prepared by adding 99.9% by weight of water to 1% by weight of Cissus quadrangularis powder, stirring at room temperature at high speed for 2.5 minutes, stirring at low speed for 2.5 minutes, and then sonicating for 3 minutes. .
실시예 1. 항산화 활성Example 1. Antioxidant activity
비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물의 항산화 활성을 측정하기 위해, 에탄올 100㎖에 DPPH(α,α'-diphenyl-β-picrylhydrazyl) 16㎎을 녹이고 증류수 100㎖을 혼합한 후 Whatman 필터지 NO. 2에 여과시켜 DPPH 반응 용액을 제조하였다. 제조예 1에서 제조한 시서스 쿼드란굴라리스 추출물과 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물을 10%(w/v)의 농도로 각각 만들어 1㎖를 취한 후 DPPH 반응 용액 5㎖을 넣어 혼합하고 암소에서 30분간 반응시킨 다음 분광광도계를 이용하여 528nm에서 흡광도를 측정하였다. 이때 활성 비교를 위하여 기존에 항산화제로 많이 사용되고 있는 합성 항산화제 BHT(butylated hydroxytoluene)를 0.05% 농도로 사용하여 시료와 동일한 방법으로 흡광도를 측정하였다. DPPH 라디칼 소거능 활성(radical scavenging activity)을 구하는 식은 하기와 같다.To measure the antioxidant activity of a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis, 16 mg of DPPH (α,α'-diphenyl-β-picrylhydrazyl) was dissolved in 100 ml of ethanol and dissolved in 100 ml of distilled water. After mixing ㎖, Whatman filter paper NO. DPPH reaction solution was prepared by filtration. A mixture of the Cissus quadrangularis extract prepared in Preparation Example 1, unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis was prepared at a concentration of 10% (w/v), and 1 ml was taken. Then, 5 ml of DPPH reaction solution was added and mixed, reacted in the dark for 30 minutes, and absorbance was measured at 528 nm using a spectrophotometer. At this time, to compare the activity, BHT (butylated hydroxytoluene), a synthetic antioxidant widely used as an antioxidant, was used at a concentration of 0.05% and the absorbance was measured in the same manner as the sample. The equation for calculating DPPH radical scavenging activity is as follows.
DPPH 라디칼 소거 활성(%)=[1-(시료 첨가 흡광도/시료 무첨가 흡광도)]×100DPPH radical scavenging activity (%) = [1-(absorbance with sample added/absorbance without sample added)]×100
그 결과, 도 1에 개시한 바와 같이 시서스 쿼드란굴라리스 추출물 첨가구와 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물 첨가구에서 DPPH 라디칼 소거활성을 나타내는 것을 확인하였다.As a result, as shown in Figure 1, it was confirmed that DPPH radical scavenging activity was shown in the Cissus quadrangularis extract and the mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis. .
실시예 2. 항비만 효과Example 2. Anti-obesity effect
(1) 췌장 리파아제(pancreatic lipase) 저해 활성(1) Pancreatic lipase inhibitory activity
췌장 리파아제(Pancreatic lipase) 저해활성은 시료 3g에 80% 메탄올을 이용하여 24시간 동안 실온에서 진탕 추출한 후 100㎖로 정용한 후 시료로 이용하였다. 돼지 췌장 리파아제(porcine pancreatic lipase) 0.3mg에 10mM MOPS와 1mM EDTA(pH 6.8)를 포함하는 완충액을 30㎕를 넣고 트리스 완충액(100mM tris-HCl, 5mM CaCl2, pH 7.0)를 850㎕ 첨가하여 효소 완충액(enzyme buffer)을 준비하였다. 효소 완충액에 시료 20㎕를 첨가하여 37℃에서 15분간 반응시켰다. 반응 후 10mM ρ-니트로페닐 뷰티레이트(Sigma-Aldrich Co., USA) 20㎕를 첨가하여 다시 37℃에서 15분간 반응시켰다. ρ-니트로페닐 뷰티레이트(ρ-nitrophenyl butyrate)가 ρ-니트로페놀(ρ-nitrophenol)로 가수분해된 정도를 ELISA 리더(Infinite 200 TECAN, Bio tex, Austria)를 사용하여 흡광도 400nm에서 측정하였다. EGCG(Epigallro Catechine Gallate)는 양성대조군으로 사용하였다. 리파아제 저해활성(%)은 다음과 같이 계산하였다.Pancreatic lipase inhibitory activity was measured by shaking and extracting 3 g of the sample with 80% methanol for 24 hours at room temperature, then diluting to 100 ml and using it as a sample. Add 30㎕ of buffer containing 10mM MOPS and 1mM EDTA (pH 6.8) to 0.3mg of porcine pancreatic lipase, and add 850㎕ of Tris buffer (100mM tris-HCl, 5mM CaCl2, pH 7.0) to make enzyme buffer. (enzyme buffer) was prepared. 20㎕ of sample was added to the enzyme buffer and reacted at 37°C for 15 minutes. After the reaction, 20㎕ of 10mM ρ-nitrophenyl butyrate (Sigma-Aldrich Co., USA) was added and the reaction was allowed to proceed at 37°C for 15 minutes. The extent to which ρ-nitrophenyl butyrate was hydrolyzed to ρ-nitrophenol was measured at absorbance at 400 nm using an ELISA reader (Infinite 200 TECAN, Bio tex, Austria). EGCG (Epigallro Catechine Gallate) was used as a positive control. Lipase inhibitory activity (%) was calculated as follows.
췌장 리파아제 저해 활성(%)={1-[(B-C)/A]}×100Pancreatic lipase inhibitory activity (%)={1-[(B-C)/A]}×100
A : 시료 무첨가 흡광도A: Absorbance without sample addition
B : 시료 첨가 흡광도B: Absorbance of sample addition
C: 효소 무첨가 흡광도C: Absorbance without enzyme addition
그 결과, 도 2에 개시한 바와 같이 시서스 쿼드란굴라리스 추출물 단독에 비해 본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물 처리군에서 췌장 리파아제 저해 활성이 현저하게 증가된 것을 확인할 수 있었다.As a result, as shown in Figure 2, the pancreatic lipase inhibitory activity was higher in the group treated with the mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis of the present invention compared to the Cissus quadrangularis extract alone. A significant increase was confirmed.
(2) 세포생존율 측정(2) Cell viability measurement
제조예 1의 시서스 쿼드란굴라리스 추출물과 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물이 세포생존에 미치는 영향을 확인하고, 실험에 사용될 농도의 범위를 정하기 위하여 Mosmann(1983)의 방법을 이용하여 MTT(3-(4,5-dimeth-ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 분석을 실시하였다. 지방전구세포인 3T3-L1을 100㎕의 DMEM(Dulbecco' Modified Eagle’Media; Gibco)이 담긴 96 웰 플레이트에 1일 동안 배양한 후, 다양한 농도(25, 50, 100, 200㎍/㎖)의 시서스 쿼드란굴라리스 추출물; 또는 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물을 처리하여 24시간 배양하였다. 그런 다음에, 각 웰에 5㎎/㎖의 MTT 용액을 10㎕씩 분주한 후 3시간 동안 배양하면서 환원반응을 유도하였으며, 100㎕의 DMSO(dimethyl sulfoxide) 용액을 첨가하여 보라색의 포르마잔(formazan) 결정을 완전히 용해하였다. 그 후, 분광광도계를 이용하여 570㎚에서 흡광도를 측정하였으며, 시료 무처리 군의 생존율 100%를 기준으로 시료 처리군의 상대적 세포 생존율을 계산하였다. To confirm the effect of the Cissus quadrangularis extract of Preparation Example 1 and the mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis on cell survival and to determine the range of concentration to be used in the experiment. MTT (3-(4,5-dimeth-ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) analysis was performed using the method of Mosmann (1983). 3T3-L1 preadipocytes were cultured in a 96-well plate containing 100㎕ of DMEM (Dulbecco' Modified Eagle'Media; Gibco) for 1 day, and then incubated with various concentrations (25, 50, 100, 200㎍/㎖). Cissus quadrangularis extract; Alternatively, they were treated with a mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis and cultured for 24 hours. Then, 10㎕ of 5 mg/㎖ MTT solution was dispensed into each well and incubated for 3 hours to induce a reduction reaction. 100㎕ of DMSO (dimethyl sulfoxide) solution was added to produce purple formazan. ) The crystals were completely dissolved. Afterwards, the absorbance was measured at 570 nm using a spectrophotometer, and the relative cell survival rate of the sample treated group was calculated based on the 100% survival rate of the untreated sample group.
그 결과, 도 3에 개시한 바와 같이 시서스 쿼드란굴라리스 추출물과 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물 처리군에서 세포독성이 나타나지 않음을 확인하였다.As a result, as shown in Figure 3, it was confirmed that no cytotoxicity was observed in the group treated with a mixture of Cissus quadrangularis extract, unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis.
(3) 지방축적 억제 활성(3) Fat accumulation inhibition activity
지방전구세포인 3T3-L1의 지방생성 정도는 Lipid(Oil Red-O) staining kit(sigma, USA)를 이용한 염색을 통하여 측정하였다. 제조예 1의 시서스 쿼드란굴라리스 추출물; 또는 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물(50 및 100㎍/㎖); 및 분화유도물질(MDI)을 처리하여 분화시키고, 그 후 10% 포르말린이 포함된 인산완충액(phosphatate buffer saline, PBS)을 처리하여 실온에서 고정한 후, 이를 제거하고, 60% 이소프로판올(isopropanol)로 씻어준 뒤 건조하였다. 그 후, ORO(Oil-red-O) 시약을 넣고, 45분 동안 염색한 후 증류수로 4번 세척하고, 증류수를 완벽히 제거하였다. 그 후, 세포에 100% 이소프로판올을 넣고 180 rpm에서 10분 동안 지방에 염색된 ORO를 추출하고, 그 값을 520㎚ 흡광도를 이용하여 측정하였다. The degree of adipogenesis of 3T3-L1 preadipocytes was measured through staining using the Lipid (Oil Red-O) staining kit (Sigma, USA). Cissus quadrangularis extract of Preparation Example 1; or a mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis (50 and 100 μg/ml); and differentiation inducer (MDI) to differentiate, and then treated with phosphate buffer saline (PBS) containing 10% formalin to fix at room temperature, remove it, and wash with 60% isopropanol. After giving it, it was dried. Afterwards, ORO (Oil-red-O) reagent was added and dyed for 45 minutes, then washed four times with distilled water, and the distilled water was completely removed. Afterwards, 100% isopropanol was added to the cells, and the fat-stained ORO was extracted at 180 rpm for 10 minutes, and the value was measured using absorbance at 520 nm.
그 결과, 도 4에 개시한 바와 같이 시서스 쿼드란굴라리스 단독 추출물에 비해 본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물 처리군에서 농도 의존적으로 지방 축적이 더 억제되는 것을 확인할 수 있었다.As a result, as shown in Figure 4, fat accumulation was concentrated in a concentration-dependent manner in the group treated with the mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis of the present invention compared to the Cissus quadrangularis extract alone. It was confirmed that this was further suppressed.
실시예 3. α-글루코시다아제(α-glucosidase) 저해 활성Example 3. α-glucosidase (α-glucosidase) inhibitory activity
α-글루코시다아제(α-glucosidase) 저해 활성은 아파르나 등(Aparna et al., 2009, Phytother Res., 23(4), 591-596) 방법을 이용하여 측정하였다. 효소는 효모로부터 얻어진 α-글루코시다아제(Sigma, USA)를 0.2% BSA와 0.02% NaN3가 포함된 100mM 인산완충액(pH 7.0)에 0.7 U/mL가 되도록 녹여 효소용액으로 사용하였으며, ρ-니트로페닐 α-D-글루코피라노사이드(ρ-nitrophenyl α-D-glucopyranoside; Sigma, USA)는 100mM 인산완충액(pH 7.0)에 5 mM이 되게 녹여 기질용액으로 사용하였다. 더욱 상세하게는, 시서스 쿼드란굴라리스 추출물; 또는 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물;을 96-웰 플레이트에 10㎕씩 첨가하였으며, 대조군에는 10㎕의 증류수만을 처리하고, 양성대조군으로 α-글루코시다아제(α-glucosidase) 저해제인 0.1% ACA(acarbose)를 처리하였다. 시료는 효소를 첨가하지 않은 블랭크(blank)를 만들었으며, 시료를 넣은 플레이트에는 효소용액을 50㎕씩 첨가하고 블랭크를 넣은 플레이트에는 0.2% BSA와 0.02% NaN3가 포함된 100mM 인산완충액(pH 7.0)을 50㎕ 첨가하여 이를 혼합한 후 10분 동안 실온에서 전배양(preincubation)한 다음, 기질용액을 50㎕씩 첨가하고 5분 동안 실온에서 반응시킨 후 마이크로플레이트 리더(Molecular Devices, Sunnyvale, CA, USA)를 이용하여 405nm에서 흡광도를 측정하였다. 3번 반복 실시하였으며, 기질을 첨가한 후 변화된 흡광도의 차이로부터 효소 저해 활성도를 하기식과 같이 산출하였다.The α-glucosidase inhibitory activity was measured using the method of Aparna et al. (2009, Phytother Res., 23(4), 591-596). The enzyme was used as an enzyme solution by dissolving α-glucosidase (Sigma, USA) obtained from yeast to 0.7 U/mL in 100mM phosphate buffer (pH 7.0) containing 0.2% BSA and 0.02% NaN 3. Nitrophenyl α-D-glucopyranoside (ρ-nitrophenyl α-D-glucopyranoside; Sigma, USA) was dissolved to 5 mM in 100mM phosphate buffer (pH 7.0) and used as a substrate solution. More specifically, Cissus quadrangularis extract; Or a mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis; 10 ㎕ each was added to a 96-well plate, the control group was treated with only 10 ㎕ distilled water, and α-glucosid as a positive control group. It was treated with 0.1% ACA (acarbose), an α-glucosidase inhibitor. A blank without enzyme was prepared for the sample. 50㎕ of enzyme solution was added to each plate containing the sample, and 100mM phosphate buffer (pH 7.0) containing 0.2% BSA and 0.02% NaN3 was added to the plate containing the blank. Add 50 ㎕ and mix, preincubate at room temperature for 10 minutes, then add 50 ㎕ of substrate solution at a time and react at room temperature for 5 minutes, followed by microplate reader (Molecular Devices, Sunnyvale, CA, USA). ) was used to measure the absorbance at 405 nm. This was repeated three times, and the enzyme inhibitory activity was calculated from the difference in absorbance after adding the substrate as shown in the following equation.
효소활성 저해도(%) = {(1-[(ODS-ODB)/C)]}×100Enzyme activity inhibition (%) = {(1-[(ODS-ODB)/C)]}×100
ODS: 시료 첨가 흡광도ODS: sample addition absorbance
ODB: 효소 무첨가 흡광도ODB: Absorbance without enzyme addition
C: 시료 무첨가 흡광도C: Absorbance without sample addition
그 결과, 도 5에 개시한 바와 같이 시서스 쿼드란굴라리스 단독 추출물에 비해 본 발명의 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물 처리군에서 α-글루코시다아제 저해 활성이 더 우수하였으며, 양성대조군인 ACA와 유사한 수준의 효과를 나타내었다.As a result, as shown in Figure 5, α-glucosidase was higher in the group treated with the mixture of unrefined cane sugar, lecithin, castor oil, and Cissus quadrangularis of the present invention compared to the Cissus quadrangularis extract alone. The inhibitory activity was superior and showed a similar level of effect as the positive control ACA.
Claims (9)
1) 비정제 사탕수수당 및 레시틴에 물을 첨가하여 혼합하는 단계;
2) 상기 단계 1)의 혼합물에 피마자유를 첨가하여 혼합하는 단계; 및
3) 상기 단계 2)의 최종 혼합물에 시서스 쿼드란굴라리스(Cissus quadrangularis) 분말 및 물을 첨가하여 혼합한 후, 초음파 처리하는 단계;를 포함하여 제조되는 것을 특징으로 하는 비만 및 당뇨병의 예방 또는 개선용 건강기능식품 조성물.The method of claim 1, wherein the mixture is
1) Adding and mixing unrefined cane sugar and lecithin with water;
2) adding castor oil to the mixture of step 1) and mixing; and
3) adding and mixing Cissus quadrangularis powder and water to the final mixture of step 2), followed by ultrasonic treatment; prevention of obesity and diabetes, characterized in that it is manufactured, or Health functional food composition for improvement.
2) 상기 단계 1)의 혼합물에 피마자유를 첨가하여 혼합하는 단계; 및
3) 상기 단계 2)의 최종 혼합물에 시서스 쿼드란굴라리스(Cissus quadrangularis) 분말 및 물을 첨가하여 혼합한 후, 초음파 처리하는 단계;를 포함하여 제조되는 것을 특징으로 하는 항비만 및 항당뇨 효과를 갖는 비정제 사탕수수당, 레시틴, 피마자유 및 시서스 쿼드란굴라리스의 혼합물의 제조 방법.1) Adding and mixing unrefined cane sugar and lecithin with water;
2) adding castor oil to the mixture of step 1) and mixing; and
3) Cissus quadrangularis powder and water are added to the final mixture of step 2), mixed, and then sonicated. Anti-obesity and anti-diabetic effects, characterized in that the preparation includes A method for producing a mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220135973A KR20240055976A (en) | 2022-10-20 | 2022-10-20 | Composition for preventing, ameliorating or treating obesity and diabetes mellitus comprising mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220135973A KR20240055976A (en) | 2022-10-20 | 2022-10-20 | Composition for preventing, ameliorating or treating obesity and diabetes mellitus comprising mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as effective component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240055976A true KR20240055976A (en) | 2024-04-30 |
Family
ID=90884872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220135973A KR20240055976A (en) | 2022-10-20 | 2022-10-20 | Composition for preventing, ameliorating or treating obesity and diabetes mellitus comprising mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20240055976A (en) |
-
2022
- 2022-10-20 KR KR1020220135973A patent/KR20240055976A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20170132705A (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
| KR102478724B1 (en) | A composition for diabetes or cardiovascular disease treatment comprising a citrus fermented kombucha | |
| US20090311354A1 (en) | Composition comprising extracts or fractions of magnolia obovata thunb for treating and preventing inflammation disease | |
| KR101358197B1 (en) | Composition for promoting leptin secretion comprising specific compounds as effective component | |
| KR20160066643A (en) | Anti-diabetic composition containing the extract of actinidia arguta leaves or fractions thereof | |
| KR20110051543A (en) | Composition for preventing or treating obesity comprising blueberry fermentation extract | |
| KR20240055976A (en) | Composition for preventing, ameliorating or treating obesity and diabetes mellitus comprising mixture of unrefined cane sugar, lecithin, castor oil and Cissus quadrangularis as effective component | |
| KR20230095471A (en) | Composition for improving muscle strength comprising fermented Schisandra chinensis fruit byproduct and method for preparing the same | |
| KR102045847B1 (en) | Kyung-ok-go having high acceptability and anti-diabetes activity adding the silk of zea mays and pumpkin | |
| KR20210074865A (en) | Pharmaceutical composition for preventing or treating diabetes, including extract of fermented tea leaves | |
| KR101344564B1 (en) | Composition comprising extract of hot peppers and Chinese peppers for preventing or treating of obesity or hyperlipidemia | |
| KR20200129596A (en) | Composition for Preventing or Treating of Degenerative Brain Disease Comprising Extract of Zanthoxylum piperitum Fruit | |
| KR20200089527A (en) | Composition comprising extracts of Acorus gramineus and Dendropanax morbifera for anti-inflammation | |
| KR102149093B1 (en) | Composition for Preventing or Treating Neurodegenerative Disease by extracts of Mate and Dendropanax morbifera | |
| KR20150113434A (en) | A composition comprising the extract of ginseng seed for protecting brain cells and preventing, improving and treating depression | |
| KR102632034B1 (en) | Composition for preventing, ameliorating or treating arthritis and joint pain comprising mixed extract of Alpiniae Oxyphyllae, Paeonia lactiflora and Glycyrrhiza uralensis as effective component | |
| KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
| KR102025572B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component | |
| WO2024117770A1 (en) | Composition including colored rice extract as active ingredient for enhancing immunity | |
| WO2023224305A1 (en) | Composition for preventing, ameliorating, or treating arthritis and joint pain comprising lysimachia mauritiana extract as active ingredient | |
| KR20230161338A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Spiraea prunifolia var. simpliciflora extract as effective component | |
| KR20050107362A (en) | Health improving food containing an extract of the root bark of ulmus davidiana var | |
| KR20230161340A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Staphylea bumalda extract as effective component | |
| KR20230166478A (en) | Composition for protecting stomach and intestines comprising Wongam fermented product as effective component | |
| KR100544711B1 (en) | FOOD COMPOSITION CONTAINING VITAMIN K.sub.3 AND QUERCETIN HAVING ANTI-CANCER EFFICACY |